Hims & Hers’ Weight-Loss Empire Hits a Gut-Wrenching End
Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...
Why cheaper alternatives to weight-loss drugs like Wegovy, Zepbound will be tougher to get
The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...
Business Insider24d
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...
Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
Business Insider16d
Analysts Have Mixed Reviews on Hims & Hers Stock Amid Uncertainty Around Weight Loss Business
Hims & Hers’ weight loss offerings will now mainly include its oral medications and the liraglutide injection, which the company plans to launch in the early second half of 2025. Also ...
Fierce Healthcare25d
Hims & Hers projects weight loss business to hit $725M in 2025 despite GLP-1 market shift
The company expanded into weight loss in late 2023 with oral medication kits and added compounded GLP-1 medications to its offerings last May. Hims & Hers also offers subscriptions for Wegovy and ...
Reuters26d
Hims & Hers warns it may stop selling compounded weight-loss drugs
Feb 24 (Reuters) - Hims & Hers (HIMS.N), opens new tab said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk (NOVOb.CO), opens new ...
Yahoo Finance25d
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
Hims and Hers plans to stop selling compounded weight loss drugs after an FDA update. Hims and Hers' stock fell over 19% in after-hours trading on Monday. The FDA removed semaglutide injections ...
Yahoo Finance25d
Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again
Hims and Hers plans to stop selling compounded weight loss drugs after an FDA update. Hims and Hers' stock fell over 19% in after-hours trading on Monday. The FDA removed semaglutide injections from ...